Atrial Fibrillation: Anticoagulation, Rate & Rhythm Control
Recognising AF, calculating stroke risk, and understanding every drug you give — an evidence-based guide for UK student nurses.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia you will meet on any ward. Around 1.6 million people in the UK live with a diagnosis — and many more are undiagnosed. It becomes exponentially more common with age, so on any ward caring for older adults you will give AF medications every single shift. Yet it is also one of the most misunderstood areas of pharmacology: students often know the drug names but not why the patient is taking them, what the real risks are, or what to check before administration.
AF matters because it is not just an irregular heartbeat — it is a major, modifiable stroke risk. Blood pools in the non-contracting atrial appendage, forms clots, and those clots travel to the brain. AF is responsible for around 20% of all ischaemic strokes, and AF-related strokes tend to be larger, more disabling, and more often fatal. As the nurse administering the medications that prevent this, your understanding is directly patient safety. This guide breaks down what you give, why you give it, and what to monitor — aligned with UK national guidance.
1. National Guidance
All content aligned with: NICE Guideline NG180 — Atrial Fibrillation: Management (2021, updated), including recommendations on stroke-risk assessment, anticoagulation choice, and rate versus rhythm control. Drug monitoring practice cross-referenced with the current BNF and NICE Technology Appraisals for direct-acting oral anticoagulants.
📎 Source: NICE NG180 — Full Guideline
⚠️ Local anticoagulation protocols and drug formularies vary. Some trusts manage warfarin via a shared-care anticoagulation clinic; others use nurse-led dosing. Always follow your trust’s specific policy and the direction of the prescriber.
2. The Four Types of AF — and Why the Type Changes Treatment
The pattern of AF determines whether the team aims to control the rate or restore the rhythm. Understanding the terminology stops you confusing “permanent” (we accept it) with “persistent” (we are still trying to cardiovert):
| Type | Definition | Usual Treatment Goal |
|---|---|---|
| Paroxysmal | Self-terminating episodes, usually < 7 days (often < 48 hours). Patient may be in sinus rhythm when you see them. | Anticoagulation by stroke risk. Rate control during episodes; ablation or antiarrhythmic if symptomatic. |
| Persistent | Continuous > 7 days, or terminated by cardioversion. Sinus rhythm can potentially be restored. | Rate control as default; consider rhythm control (cardioversion/ablation) if symptomatic or rate control fails. |
| Long-standing persistent | Continuous > 12 months. Rhythm control being considered. | Usually rate control; rhythm control only after informed discussion. |
| Permanent | AF accepted. Cardioversion not pursued — patient and clinician agree to stop trying. | Rate control + anticoagulation by stroke risk. No antiarrhythmics for rhythm. |
📎 Source: NICE NG180 — Definitions & Classification
⚠️ Always check the patient’s current rhythm before rate-controlling drugs. A patient documented as “AF” may have spontaneously cardioverted — giving a rate-lowering drug in sinus rhythm can cause dangerous bradycardia. Check the monitor or a 12-lead ECG.
3. Stroke Risk — CHA₂DS₂-VASc and When Anticoagulation Is Offered
The decision to anticoagulate is not based on whether the AF is paroxysmal or permanent — even brief episodes carry stroke risk. It is based on the patient’s individual risk score. NICE recommends using CHA₂DS₂-VASc for everyone with AF:
| Letter | Factor | Points |
|---|---|---|
| C | Congestive heart failure / LV dysfunction | 1 |
| H | Hypertension (treated or untreated) | 1 |
| A₂ | Age ≥ 75 years | 2 |
| D | Diabetes mellitus | 1 |
| S₂ | Previous Stroke / TIA / thromboembolism | 2 |
| V | Vascular disease (MI, PAD, aortic plaque) | 1 |
| A | Age 65–74 years | 1 |
| Sc | Sex category — female | 1 |
How to interpret it: A score of ≥ 2 in men or ≥ 3 in women = offer anticoagulation. A score of 1 in men or 2 in women = consider anticoagulation after discussing bleeding risk. Score 0 (men) or 1 (women, age-only) = no anticoagulation needed. Notice that a single previous stroke or TIA alone gives 2 points — these patients are always anticoagulated.
Bleeding Risk — HAS-BLED (and Why It Is Not a Reason to Withhold Treatment)
Use HAS-BLED to assess bleeding risk: Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR (if on warfarin), Elderly (> 65), Drugs (antiplatelets/NSAIDs) or alcohol excess. A score ≥ 3 flags high bleeding risk. Crucially, NICE is clear: a high HAS-BLED score is a trigger to review and correct reversible risk factors (uncontrolled BP, stop NSAIDs, reduce alcohol) — it is not a reason to deny anticoagulation, because the stroke risk usually outweighs it.
📎 Source: NICE NG180 — Stroke & Bleeding Risk Assessment
4. Anticoagulation — The Core of AF Treatment
Anticoagulation does nothing for the heart rate or the irregular rhythm. Its sole job is to prevent clot formation in the atria and therefore prevent stroke. NICE prefers a direct-acting oral anticoagulant (DOAC) over warfarin for most people with AF, unless the patient has a mechanical heart valve or moderate-to-severe mitral stenosis (where warfarin is required).
4.1 Warfarin — The Old Standard, Still Used
Warfarin is a vitamin K antagonist. It blocks vitamin K-dependent clotting factors (II, VII, IX, X). Its effect is measured by the INR — for AF the target is 2.5 (range 2.0–3.0). Below 2.0 the patient is under-protected from stroke; above 3.5 bleeding risk climbs steeply. Because its effect is heavily influenced by diet (vitamin K in green leafy vegetables), alcohol, illness, and dozens of drug interactions, INR must be monitored regularly — typically weekly when unstable, extending to up to 12-weekly when stable.
- Check the latest INR before giving — if it is above range or missing, clarify with the prescriber/anticoagulation clinic.
- Watch for interactions: Many antibiotics (e.g. macrolides, metronidazole) and antifungals potentiate warfarin and can send INR soaring — expect extra INR checks.
- Teach consistency, not avoidance: Patients should keep vitamin K intake steady — sudden large changes (cranberry juice, alcohol binges, new diets) destabilise INR.
- Bleeding signs: Bruising, bleeding gums, nosebleeds, blood in urine/stool, black tarry stools, severe headache — report immediately. Reversal: vitamin K and prothrombin complex concentrate (beriplex) in major bleeding.
4.2 DOACs — Apixaban, Rivaroxaban, Dabigatran, Edoxaban
Direct-acting oral anticoagulants target a single clotting factor directly. They have a rapid onset, shorter half-life, fewer food interactions, and no routine INR monitoring — which is why patients often prefer them. There are two classes:
- Direct thrombin inhibitors: Dabigatran. Reversal agent: idarucizumab (Praxbind).
- Factor Xa inhibitors: Apixaban, rivaroxaban, edoxaban. Reversal agent: andexanet alfa (in major bleeding).
| Drug | Usual AF Dose | Key Nursing Point |
|---|---|---|
| Apixaban (Eliquis) | 5 mg twice daily (2.5 mg BID if ≥ 2 of: age ≥80, weight ≤60 kg, creatinine ≥133 µmol/L) | Twice daily — do not double up if missed. Renal function checked at least annually. |
| Rivaroxaban (Xarelto) | 20 mg once daily (15 mg if eGFR 15–49) | Take with food — improves absorption. Once daily. |
| Edoxaban (Lixiana) | 60 mg once daily (30 mg if weight ≤60 kg, CrCl 15–50, or certain P-gp inhibitors) | Once daily. Not used if CrCl > 95 (reduced efficacy). |
| Dabigatran (Pradaxa) | 150 mg twice daily (110 mg BID if ≥80 or high bleed risk) | Taken as whole capsule — do not open (increases absorption). Gastrointestinal upset common; take with food. |
All DOACs are renally cleared to varying degrees. Check eGFR/creatinine before starting and at least annually (more often in the elderly or declining renal function). A dose that was safe six months ago may now be accumulating and causing bleeding. If a patient on a DOAC is acutely unwell with sepsis, vomiting, or AKI — renal function can drop fast; flag to the medical team that a dose review is needed.
📎 Sources: NICE NG180 — Choice of Anticoagulant | Monitoring & Review
⚠️ Antiplatelets (aspirin/clopidogrel) are NOT stroke prevention in AF. NICE is explicit: aspirin monotherapy should not be offered for stroke prevention in AF — it is less effective than anticoagulants and carries its own bleeding risk. If you see a patient with AF on aspirin alone, flag it for prescriber review.
5. Rate Control vs Rhythm Control — and the Drugs Behind Each
NICE recommends rate control as the default first-line strategy for most people with AF — it is simpler, equally effective at reducing symptoms in many patients, and avoids the risks of antiarrhythmic drugs. Rhythm control (restoring sinus rhythm) is considered if symptoms persist despite rate control, if the AF has a reversible cause, or if the patient is younger and symptomatic.
5.1 Rate-Control Drugs — Slow the Ventricle, Calm the Symptoms
In AF the atria fibrillate at 300–600 bpm, but only some impulses reach the ventricles. Rate control slows conduction through the AV node so the ventricles beat at a manageable rate (usually resting < 100 bpm, personalised).
| Drug (Class) | Why Given | Nursing Checks & Cautions |
|---|---|---|
| Bisoprolol / Atenolol (Beta-blocker) — first-line | Slows AV conduction; also reduces ischaemia and anxiety-related tachycardia. Standard first choice. | Check apical pulse and BP before each dose — hold and seek advice if pulse < 50–60 (per local policy) or systolic BP < 90. Contraindicated in severe asthma; caution in COPD. Do not stop abruptly (rebound tachycardia). |
| Diltiazem / Verapamil (rate-limiting calcium-channel blocker) | Alternative first-line if beta-blockers contraindicated (e.g. asthma). | Check pulse/BP. Never combine verapamil with a beta-blocker — risk of severe bradycardia/asystole. Constipation common (diltiazem less so). |
| Digoxin (cardiac glycoside) | Slows AV conduction; good for sedentary/elderly patients or as add-on. No effect on exercise heart rate. | Count apical pulse for a full minute before giving — hold if < 60 (local policy). Narrow therapeutic index: toxicity signs = nausea/vomiting, confusion, yellow/green visual halos, bradycardia/arrhythmias. Hypokalaemia greatly increases toxicity — check K⁺. Levels checked 6+ hours post-dose. |
| Amiodarone (class III antiarrhythmic) | Used for rate control when others fail, and for rhythm control/chemical cardioversion. | Very long half-life (weeks). Monitor LFTs, TFTs, chest (pulmonary toxicity). Photosensitivity — advise sun protection. Corneal microdeposits (reversible). Numerous interactions — check every new prescription. |
5.2 Rhythm-Control Drugs — Restoring Sinus Rhythm
Rhythm control may be electrical (DC cardioversion) or chemical (drugs), and long-term with catheter ablation. Antiarrhythmics are higher-risk and usually initiated by specialists:
- Flecainide (class Ic): Used in structurally normal hearts — contraindicated in ischaemic heart disease or LV dysfunction. Can be used as “pill-in-the-pocket” for self-termination of paroxysmal AF.
- Amiodarone: The usual choice in structural heart disease (as above).
- DC cardioversion: If AF > 48 hours, patient must be anticoagulated for at least 3 weeks before (or have a TOE ruling out thrombus) and 4 weeks after — this is why anticoagulation timing matters.
📎 Source: NICE NG180 — Rate & Rhythm Control
⚠️ Local rate-control targets and “hold” parameters vary. Some trusts say hold digoxin if pulse < 60; others < 50. Know your ward’s policy — and always document why you held a dose and who you informed.
6. Red Flags — When to Escalate Urgently
Most AF is stable and chronic. These are the situations that need immediate senior review:
| Clinical Trigger | Risk | Immediate Nursing Action |
|---|---|---|
| Fast AF with haemodynamic instability — systolic BP < 90, chest pain, acute heart failure, reduced consciousness | Cardiogenic shock / myocardial ischaemia | Call 2222 / crash team. Prepare for urgent DC cardioversion. Oxygen, IV access, continuous monitoring. |
| New focal neurological signs — FAST positive | Stroke — the very complication anticoagulation prevents | Time-critical. Call 2222, activate hyper-acute stroke pathway. Do NOT delay — thrombolysis/thrombectomy windows are short. |
| Major bleeding on anticoagulant — active bleeding, falling Hb, haemodynamic instability | Haemorrhagic shock; intracranial bleed if head injury | Stop anticoagulant. Call 2222. Identify which drug (for reversal agent). IV access, cross-match, monitor GCS if head involved. |
| Digoxin toxicity suspected — vomiting, confusion, visual disturbance, bradycardia/arrhythmia | Life-threatening arrhythmia; often precipitated by hypokalaemia | Hold dose, check U&E (especially K⁺) and digoxin level, escalate. Continuous cardiac monitoring. |
| INR > 5 (warfarin) or any INR with bleeding | Spontaneous haemorrhage | Hold warfarin, escalate per anticoagulation protocol — may need vitamin K. |
📎 Source: NICE NG180 — Urgent Referral & Escalation
⚠️ Emergency stroke and major-bleeding protocols vary by trust. Know your ward’s thrombolysis call criteria and where the reversal agents are kept.
7. Your Daily Practice — The Checks That Prevent Harm
Before you give any AF medication on a drug round, run through this quick mental checklist:
- Pulse & BP: For rate-lowering drugs (beta-blockers, diltiazem, digoxin) — check apical/radial pulse and BP. Hold and escalate if below your trust’s threshold.
- Latest bloods: INR (warfarin), U&E/eGFR and K⁺ (all — hypokalaemia worsens digoxin toxicity; renal function drives DOAC dose).
- Rhythm check: Is the patient actually in AF right now? If they have spontaneously cardioverted, rate-lowering drugs may be inappropriate — flag.
- Bleeding signs: Every patient on an anticoagulant — ask about bruising, bleeding gums, nosebleeds, urine/stool colour, headaches.
- New prescriptions: Any new antibiotic or interacting drug? Expect warfarin INR to swing; DOAC dose may need renal review.
- Adherence & timing: Rivaroxaban with food; dabigatran capsules swallowed whole; twice-daily drugs spaced correctly. Missed-dose advice varies — check the patient information leaflet.